- #1
- 4,779
- 3,842
- TL;DR Summary
- FDA approved today 22--Sep-2021 booster shots (Pfizer COVID vaccine) for seniors 65+, immunocompromised, and health care workers
The second category is "individuals 18 through 64 years of age at high risk of severe COVID-19". That's the same language describing the category that was allowed early access to the vaccine in March. It isn't just "immunocompromised". It March, it was anyone with at least two of about 11 factors that made COVID especially dangerous - thing like diabetes, kidney disease, obesity, and immunocompromised.jim mcnamara said:Summary:: FDA approved today 22--Sep-2021 booster shots (Pfizer COVID vaccine) for seniors 65+, immunocompromised, and health care workers
https://www.fda.gov/news-events/pre...biontech-covid-19-vaccine-certain-populations
I think "metabolic syndrome" needs to become part of the vernacular.jim mcnamara said:terms like metabolic syndrome, ...
Or perhaps it is enough to say "get fat and you'll die much sooner".... by 2012, more than a third of all US adults met the definition and criteria for metabolic syndrome agreed to jointly by several international organizations.
This means that the US Food and Drug Administration (FDA) has officially authorized the use of a third dose of the Pfizer-BioNTech Covid-19 vaccine for individuals aged 65 and older. This is in addition to the two doses that were previously recommended for full vaccination.
Studies have shown that older individuals may have a weaker immune response to the Covid-19 vaccine, compared to younger individuals. This can put them at a higher risk for breakthrough infections or waning immunity over time. A booster shot can help strengthen their immune response and provide additional protection against the virus.
The FDA has authorized the booster shot for individuals aged 65 and older who have completed their initial two-dose series of the Pfizer-BioNTech vaccine at least 6 months ago. This includes individuals who are at increased risk for severe Covid-19 due to underlying medical conditions or occupational exposure.
The FDA has determined that the benefits of receiving a booster shot for seniors outweigh the potential risks. The safety and effectiveness of the booster shot have been evaluated through clinical trials and data from other countries where it has already been authorized. As with any vaccine, there may be some mild side effects, but these are typically short-lived and not serious.
The FDA recommends that seniors receive the booster shot at least 6 months after completing their initial two-dose series of the Pfizer-BioNTech vaccine. However, individuals who are at increased risk for severe Covid-19 may choose to receive the booster shot earlier, after consulting with their healthcare provider.